These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 35912841)

  • 21. The potential of using biodegradable microspheres in retinal diseases and other intraocular pathologies.
    Herrero-Vanrell R; Bravo-Osuna I; Andrés-Guerrero V; Vicario-de-la-Torre M; Molina-Martínez IT
    Prog Retin Eye Res; 2014 Sep; 42():27-43. PubMed ID: 24819336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Self-implantable double-layered micro-drug-reservoirs for efficient and controlled ocular drug delivery.
    Than A; Liu C; Chang H; Duong PK; Cheung CMG; Xu C; Wang X; Chen P
    Nat Commun; 2018 Nov; 9(1):4433. PubMed ID: 30401883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Updates on Biodegradable Formulations for Ocular Drug Delivery.
    Tsung TH; Chen YH; Lu DW
    Pharmaceutics; 2023 Feb; 15(3):. PubMed ID: 36986595
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Considerations for Polymers Used in Ocular Drug Delivery.
    Allyn MM; Luo RH; Hellwarth EB; Swindle-Reilly KE
    Front Med (Lausanne); 2021; 8():787644. PubMed ID: 35155469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety evaluation of ocular drug delivery formulations: techniques and practical considerations.
    Short BG
    Toxicol Pathol; 2008 Jan; 36(1):49-62. PubMed ID: 18337221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-acting formulation strategies for protein and peptide delivery in the treatment of PSED.
    Garkal A; Bangar P; Rajput A; Pingale P; Dhas N; Sami A; Mathur K; Joshi S; Dhuri S; Parikh D; Mutalik S; Mehta T
    J Control Release; 2022 Oct; 350():538-568. PubMed ID: 36030993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro dissolution testing models of ocular implants for posterior segment drug delivery.
    Adrianto MF; Annuryanti F; Wilson CG; Sheshala R; Thakur RRS
    Drug Deliv Transl Res; 2022 Jun; 12(6):1355-1375. PubMed ID: 34382178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging potential of niosomes in ocular delivery.
    Verma A; Tiwari A; Saraf S; Panda PK; Jain A; Jain SK
    Expert Opin Drug Deliv; 2021 Jan; 18(1):55-71. PubMed ID: 32903034
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research.
    Cobb DA; Smith NA; Edagwa BJ; McMillan JM
    Expert Opin Drug Deliv; 2020 Sep; 17(9):1227-1238. PubMed ID: 32552187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Controlled diffusional release of dispersed solute drugs from biodegradable implants of various geometries.
    Collins R; Paul Z; Reynolds DB; Short RF; Wasuwanich S
    Biomed Sci Instrum; 1997; 33():137-42. PubMed ID: 9731349
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intraocular implants for extended drug delivery: therapeutic applications.
    Bourges JL; Bloquel C; Thomas A; Froussart F; Bochot A; Azan F; Gurny R; BenEzra D; Behar-Cohen F
    Adv Drug Deliv Rev; 2006 Nov; 58(11):1182-202. PubMed ID: 17107737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liposomes as vehicles for topical ophthalmic drug delivery and ocular surface protection.
    López-Cano JJ; González-Cela-Casamayor MA; Andrés-Guerrero V; Herrero-Vanrell R; Molina-Martínez IT
    Expert Opin Drug Deliv; 2021 Jul; 18(7):819-847. PubMed ID: 33412914
    [No Abstract]   [Full Text] [Related]  

  • 33. Microneedle array systems for long-acting drug delivery.
    Vora LK; Moffatt K; Tekko IA; Paredes AJ; Volpe-Zanutto F; Mishra D; Peng K; Raj Singh Thakur R; Donnelly RF
    Eur J Pharm Biopharm; 2021 Feb; 159():44-76. PubMed ID: 33359666
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-acting HIV pre-exposure prophylaxis (PrEP) approaches: recent advances, emerging technologies, and development challenges.
    Agrahari V; Anderson SM; Peet MM; Wong AP; Singh ON; Doncel GF; Clark MR
    Expert Opin Drug Deliv; 2022 Oct; 19(10):1365-1380. PubMed ID: 36252277
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preparation of dexamethasone ophthalmic implants: a comparative study of in vitro release profiles.
    Prata AI; Coimbra P; Pina ME
    Pharm Dev Technol; 2018 Mar; 23(3):218-224. PubMed ID: 28300463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ocular drug delivery to the anterior segment using nanocarriers: A mucoadhesive/mucopenetrative perspective.
    Dave RS; Goostrey TC; Ziolkowska M; Czerny-Holownia S; Hoare T; Sheardown H
    J Control Release; 2021 Aug; 336():71-88. PubMed ID: 34119558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intracorneal injection of a detachable hybrid microneedle for sustained drug delivery.
    Lee K; Song HB; Cho W; Kim JH; Kim JH; Ryu W
    Acta Biomater; 2018 Oct; 80():48-57. PubMed ID: 30267886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo tissue distribution and efficacy studies for cyclosporin A loaded nano-decorated subconjunctival implants.
    Yavuz B; Bozdağ Pehlivan S; Kaffashi A; Çalamak S; Ulubayram K; Palaska E; Çakmak HB; Ünlü N
    Drug Deliv; 2016 Nov; 23(9):3279-3284. PubMed ID: 27027148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug delivery systems for vitreoretinal diseases.
    Yasukawa T; Ogura Y; Tabata Y; Kimura H; Wiedemann P; Honda Y
    Prog Retin Eye Res; 2004 May; 23(3):253-81. PubMed ID: 15177203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent advances in intraocular sustained-release drug delivery devices.
    Cao Y; Samy KE; Bernards DA; Desai TA
    Drug Discov Today; 2019 Aug; 24(8):1694-1700. PubMed ID: 31173915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.